Literature DB >> 28789924

Constitutive interaction between 4-1BB and 4-1BBL on murine LPS-activated bone marrow dendritic cells masks detection of 4-1BBL by TKS-1 but not 19H3 antibody.

Achire N Mbanwi1, Gloria H Y Lin1, Kuan Chung Wang1, Tania H Watts2.   

Abstract

4-1BB is a TNFR family member associated with NF-κB mediated survival signaling. 4-1BB is widely expressed on activated cells of the immune system, including activated T cells, NK cells and dendritic cells. Its ligand, 4-1BBL, is transiently expressed on activated antigen presenting cells and at low levels on activated T cells. Although 4-1BBL-deficient mice clearly demonstrate a role for 4-1BBL in CD8 T cell responses to viruses such as influenza, 4-1BBL can be difficult to detect following infection of mice. Here we provide evidence for a constitutive interaction between endogenous 4-1BB and 4-1BBL on LPS activated bone marrow-derived murine dendritic cells that can mask its detection, with implications for measurement of 4-1BBL expression. The masking of 4-1BBL by its receptor results in loss of reactivity to the anti-4-1BBL antibody TKS-1, whereas the 19H3 antibody binds to 4-1BBL in the presence or absence of 4-1BB. Moreover, 4-1BB/4-1BBL interaction can occur in trans between 4-1BB+/+ and 4-1BB-/- dendritic cells in culture. These data suggest that 19H3 is the preferable antibody to use to detect 4-1BBL in the presence of its receptor.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  19H3; 4-1BB; 4-1BBL; Antibody blocking; Dendritic cells; TKS-1

Mesh:

Substances:

Year:  2017        PMID: 28789924     DOI: 10.1016/j.jim.2017.08.001

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  1 in total

1.  Soluble CD137 Ameliorates Acute Type 1 Diabetes by Inducing T Cell Anergy.

Authors:  Arata Itoh; Lorenzo Ortiz; Kritika Kachapati; Yuehong Wu; David Adams; Kyle Bednar; Shibabrata Mukherjee; Claire Chougnet; Robert S Mittler; Yi-Guang Chen; Laurence Dolan; William M Ridgway
Journal:  Front Immunol       Date:  2019-11-07       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.